Condition: Small-cell Lung Cancer · Extensive-stage Small-cell Lung Cancer · Lung Cancer · Sponsor: University of Chicago
This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.
This description comes directly from the study's public registry record.
Cancer Clinical Trials Office · 1-855-702-8222 · cancerclinicaltrials@bsd.uchicago.edu
Aditya Juloori, MD · PhaseIICRA@medicine.bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| University of Chicago Medicine | Chicago, Illinois, United States | Recruiting |
| University of Wisconsin Carbone Cancer Center | Madison, Wisconsin, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05068232